Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:80202 |
Name | adenoid cystic carcinoma |
Definition | An adenocarcinoma that is characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer pharynx cancer oropharynx cancer tonsil cancer adenoid cystic carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
FGFR2 S252W | Erdafitinib | adenoid cystic carcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00770263 | Phase I | Erlotinib + Temsirolimus | Erlotinib and Temsirolimus for Solid Tumors | Completed | USA | 0 |
NCT02098538 | Phase II | Regorafenib | Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma | Completed | USA | 0 |
NCT02780310 | Phase II | Lenvatinib | Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma | Active, not recruiting | USA | 0 |
NCT02783300 | Phase I | GSK3326595 | Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NHL) | Completed | USA | NLD | FRA | CAN | 0 |
NCT03087019 | Phase II | Pembrolizumab | Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma | Completed | USA | 0 |
NCT03172624 | Phase II | Ipilimumab + Nivolumab | Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer | Active, not recruiting | USA | 0 |
NCT03287427 | Phase I | TetMYB + Tislelizumab | MYPHISMO: MYB and PD-1 Immunotherapies Against Multiple Oncologies Trial (MYPHISMO) | Completed | AUS | 0 |
NCT03422679 | Phase Ib/II | CB-103 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | Terminated | USA | FRA | ESP | DEU | CHE | 1 |
NCT03556228 | Phase I | VMD-928 | Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | Recruiting | USA | 1 |
NCT03691207 | Phase II | BMS-906024 | A Study Of AL101 In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations (ACCURACY) | Completed | USA | NLD | ISR | GBR | FRA | CAN | 0 |
NCT03990571 | Phase II | Avelumab + Axitinib | Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma | Completed | USA | 0 |
NCT04209660 | Phase II | Lenvatinib + Pembrolizumab | Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers | Active, not recruiting | USA | 0 |
NCT04973683 | Phase I | BMS-906024 | AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer | Active, not recruiting | USA | 0 |
NCT05074940 | Phase II | Amivantamab-vmjw | Amivantamab in Adenoid Cystic Carcinoma | Recruiting | USA | 0 |
NCT05774899 | Phase Ib/II | Abemaciclib + CB-103 CB-103 + Lenvatinib | CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC | Active, not recruiting | USA | 0 |
NCT05884320 | Phase II | Sacituzumab govitecan-hziy | Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Salivary Gland Cancers | Recruiting | USA | 0 |
NCT05930951 | Phase I | MEN1309 Balstilimab + MEN1309 | Study of OBT076 Associated or Not in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck (AdCC_2023-01) | Suspended | FRA | 0 |
NCT06118086 | Phase I | REM-422 | Study of REM-422 in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma | Recruiting | USA | 0 |
NCT06322576 | Phase II | PNT2002 | 177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma | Not yet recruiting | USA | 0 |
NCT06462183 | Phase I | RGT-61159 | Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC) | Recruiting | USA | CAN | 0 |